Phase 3 N=80 Bacterial Decolonization to Prevent Radiation Dermatitis
Radiation Dermatitis
Primary: Number of Participants With Incidence of High Grade Radiation Dermatitis — 0; 9 Participants — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=48 Reducing Bacteria That Cause Tooth Decay
Caries, Dental · Cariostatic Agents
Primary: Microbial Levels — 11; 7; 15; 15 Participants — p=0.35
Phase 1 N=1 FMT for Multidrug Resistant Organism Reversal
Infection With Multi-drug Resistant Organisms
Primary: Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events) — 0; 1 Participants
N/A N=32 Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota
Human Gut Microbiota
Primary: Bacteria Prevalence in Stool — 22.3; 20.9; 18.0; 25.5 percentage of bacterial genera in stool — p=<0.05
N/A N=20 Reduction of Bacteriuria in Subjects Practicing Intermittent Catheterization
Bacteriuria
Primary: Total Bacteria Count Change From Baseline and After 24 Hours. — -62519; 57448 CFU/mL — p=0.6250
Phase 2 N=8 Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Crohn's Disease
Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale
Phase 4 N=28 Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization
Human Microbiome
Primary: Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization — -781 fg/uL
Phase 1 N=5 Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Atopic Dermatitis
Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance
N/A N=20 Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
Postoperative Wound Infection Deep Incisional Surgical Site · Prosthesis and Implants · Surgical Site Infection
Primary: Number of Participants With Bacterial Growth Before and After Photodynamic Treatment and After Skin Antisepsis — 10; 10; 3; NA Participants
N/A N=23 Device to Reduce Surgery Site Contamination - Spine
Surgery
Primary: Surgery Site CFU Density — 3.08; 1.73 CFU/m3
Phase 4 N=293 Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination
Skin Flora Contamination
Primary: Change in Number of Unique Bacterial Isolates From Pre-skin Preparation to Post-CABG - Sternal Site — -1.34; -1.31 isolates — p=0.655
Phase 4 N=103 The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria
Infectious Disease of Digestive Tract
Primary: Number of Participants With Combination of Gastrointestinal Tract Colonization With Multi-drug Resistant Gram-negative Bacteria, C. Difficile and VRE — 8; 8 Participants
Phase 2 N=28 In Vivo Preoperative Skin Preparation Efficacy Study Within a Defined Product Coverage Area
Surgical Skin Preparation · Surgical Procedure, Unspecified
Primary: Comparison of Log Change of Skin Flora Relative to Pre-treatment (Baseline) in Each of 3 Sampling Sites at a Defined Post-treatment Sampling Time. — -2.19; -1.85; -2.42…
Phase 4 N=89 Probiotics to Promote Intestinal Health
Communicable Diseases · Infection · Anti-Infective Agents
Primary: Number of Participants With Acquisition of Any New Antibiotic-resistant Organism — 9; 12 Participants
Phase 2 N=113 Impact of Probiotics for Reducing Infections in Veterans: The IMPROVE Study
Anti-biotic Resistance
Primary: Oral L. Rhamnosus HN001 Therapy Compared to Placebo on Gastrointestinal and Extra-gastrointestinal Colonization of S. Aureus. — 9; 17; 25; 24 Participants
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
Phase 1 N=21 Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Primary Sclerosing Cholangitis · Biliary Atresia
Primary: Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia — 10; 0; 0; 0 participants
Phase 3 N=69 Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
Rectal Cancer
Primary: Number of Participants Who Completed MSKCC Bowel Function Instrument (BFI Score) in Patients Following Anterior Resection (AR) or Sphincter Preserving Surgery (SPS) for…
Phase 2 N=15 The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome
End Stage Renal Disease
Primary: Change in Plasma Concentration Measure of Indoxyl Sulphate (IS) — -25.31; 9.71 µM/ml
Phase 4 N=162 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Bacterial Conjunctivitis
Primary: Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation — 0; 0; 0; 0 Percent of resistant isolates
Phase 3 N=554 Preoperative Chlorhexidine Gluconate (CHG) Cloth on Healthy Subjects
Surgery
Primary: Percent Responder Rates (%) of Bacterial Reduction on the Abdomen and Groin — 93; 86; 50; 25 Percent of Sites
Phase 2 N=24 A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System
HIV Infection · Gastrointestinal Symptoms
Primary: Effects of Daily Consumption of GanedenBC30 on Immune Function and Gastro-intestinal Issues
Phase 3 N=1,388 Preoperative CHG Cloth on Healthy Subjects
Surgery
Primary: Percent Responder Rates of Bacterial Reduction on the Abdomen and Groin Sites — 80; 75; 86; 65 % of Treated Sites
Phase 4 N=38 Rifaximin Therapy in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change in Serum Trimethylamine N-oxide (TMAO) — -3.9; 0.5 uM
N/A N=39 Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic
Infectious Disease
Primary: Treatment-associated Change in S. Aureus Colonization During a Typical 10-hour Work Day — -99.8; -13.5 Percent change in colonization — p=<0.01
N/A N=594 Reduction in IV Associated Contamination
Post-operative Infections
Primary: Presence of Bacterial IV Stopcock Lumen Contamination — 41; 32 percent stopcock contamination rate
Phase 1 N=7 Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization
Antibiotic Resistant Strain
Primary: Number of Participants With Adverse Events (NIH Grade ≥2) at Day 7 After Randomization — 4; 0 Participants
Phase 2 N=54 Targeted Microbiome Transplant in Atopic Dermatitis
Atopic Dermatitis (AD)
Primary: Per-Participant Daily Event Rate: Serious and Non-Serious Treatment Emergent Adverse Events (TEAEs) — 0.19; 0.34 events per-participant-day — p=0.075
N/A N=92 Dietary Supplement With and Without a Probiotic and/or Antibiotic
Healthy Adults
Primary: Evaluation of the Changes in Microbiome Species Abundance and Diversity From Baseline Until End of Study (Day 35) — 27.00; 31.25; 27.00; 27.00 copies/ng DNA — p=<0.0001
N/A N=36 Device to Reduce Surgery Site Contamination
Surgery
Primary: Surgery Site CFU Density — 7; 11; 0 CFU/cubic meter — p=<0.001